Safety of the combination of low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the GLobal Registry of Acute Coronary Events (GRACE)

CP Cannon; David Brieger; Frans Van de Werf; A Avezum; Gilles Montalescot; Wolfgang Lankes; BM Kennelly; Giancarlo Agnelli; Tomasz Mazurek; Rachel Kasper

Back

Shared by

Giancarlo Agnelli

University of Perugia

Safety of the combination of low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the GLobal Registry of Acute Coronary Events (GRACE)

Article 2001 en

Authors

CC
CP Cannon
DB
David Brieger
FW
Frans Van de Werf

Related publications

Article2001

Safety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE)

CP Cannon, David Brieger, Frans Van de Werf, A Avezum, A Lankes, BM Kennelly, Giancarlo Agnelli, Tomasz Mazurek, Rachel Kasper, Gilles Montalescot

Article2003

Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)

Giancarlo Agnelli, C. P. Cannon, Frans Van de Werf, Álvaro Avezum, Gilles Montalescot, Wolfgang Lankes, BM Kennelly, Tomasz Mazurek, Rachel Kasper, David Brieger

Article2007

Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)

David Brieger, Frans Van de Werf, Álvaro Avezum, Gilles Montalescot, Brian M. Kennelly, Christopher B. Granger, Shaun G. Goodman, Omar Dabbous, Giancarlo Agnelli

Article2007

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes

Omar Dabbous, Frederick A. Anderson, Joel M. Gore, Kim A. Eagle, Keith A.A. Fox, Rajendra H. Mehta, Robert J. Goldberg, Giancarlo Agnelli, Philippe Gabríel Steg

Article2012

Risk-Prediction Model for Ischemic Stroke in Patients Hospitalized With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE])

Kay Lee Park, Andrzej Budaj, Robert J. Goldberg, Frederick A. Anderson, Giancarlo Agnelli, Brian M. Kennelly, Enrique Gurfinkel, Gordon FitzGerald, Joel M. Gore

Safety of the combination of low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the GLobal Registry of Acute Coronary Events (GRACE)

Discussion(0)

Related publications

Safety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE)

Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)

Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes

Risk-Prediction Model for Ischemic Stroke in Patients Hospitalized With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE])